Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05087992 | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 5 | Feb 19, 2025 |
| clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05943041 | Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer | completed | Phase 1 | 9 | GILongevityINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04805307 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | completed | Phase 1 | 176 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02188264 | Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05278728 | Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 31 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03916510 | Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer(CEDAR) | completed | Phase 1 | 12 | University of OxfordOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04883775 | Study of a New Technique for Imaging Pancreatic Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04662112 | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma(NASOX) | completed | Phase 1 / Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03699319 | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 49 | David Bajor, MDOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02643498 | A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT03518554 | A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT01950403 | Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03698825 | TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer | completed | Phase 1 / Phase 2 | 62 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03086642 | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | completed | Phase 1 | 10 | Karie D. Runcie, MDOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01010945 | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | completed | Phase 1 | 19 | OSI PharmaceuticalsINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03374254 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | completed | Phase 1 | 116 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05784597 | A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors(FAPrimo) | completed | Phase 1 | 18 | Philogen S.p.A.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05182112 | Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver | completed | Phase 1 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04313868 | GEN2 Directed Cancer Immunotherapy Trial(GEN2) | completed | Phase 1 | 61 | GenVivo, Inc.INDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT00630552 | QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 138 | NantCell, Inc.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03087591 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 11 | Wake Forest University Health SciencesOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02754856 | Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery | completed | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03253289 | Meclizine for Hepatocellular Carcinoma(OPTIM) | completed | Phase 1 | 13 | Tannaz ArmaghnayOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | completed | Phase 1 | 129 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03565003 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 / Phase 2 | 126 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04130763 | Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1 | completed | Phase 1 | 10 | Peking UniversityOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT04713891 | A Study of KF-0210 in Advanced Solid Tumors Patients | completed | Phase 1 | 14 | Keythera Pharmaceuticals (Australia) Pty LtdINDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT04098432 | STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma(CA209-9KH) | completed | Phase 1 / Phase 2 | 15 | University Hospital Hradec KraloveOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03175679 | Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | completed | Phase 1 | 10 | Beijing YouAn HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2025source: clinicaltrials